[Lafora's disease (EPM2)]

Area of Science:

• Neurology
• Genetics
• Epilepsy

Context:

• Lafora disease (LD) is a rare, severe, and progressive myoclonus epilepsy.
• It typically manifests in adolescence with seizures, myoclonus, and cognitive deterioration.
• LD exhibits genetic heterogeneity with mutations in EPM2A (laforin) and EPM2B (malin) genes.

Purpose:

• To provide a comprehensive overview of Lafora disease, including its clinical presentation, genetic basis, diagnosis, and management.
• To highlight the diagnostic criteria and challenges associated with genetic heterogeneity.
• To emphasize the importance of symptomatic treatment and psychosocial support.

Summary:

• Lafora disease presents with diverse seizure types, myoclonus, and rapid cognitive decline, often preceded by neurological symptoms.
• Autosomal recessive inheritance is typical, with mutations in EPM2A and EPM2B accounting for most cases.
• Diagnosis is supported by clinical findings, EEG, and axillary skin biopsy revealing Lafora bodies; genetic testing aids confirmation.
• Treatment is symptomatic, focusing on seizure control, avoiding aggravating medications, and providing crucial psychological and social support.

Impact:

• Improved understanding of Lafora disease's complex presentation and genetic underpinnings.
• Enhanced diagnostic approaches through a combination of clinical, histological, and genetic methods.
• Guidance for clinical management, emphasizing symptomatic treatment and supportive care for patients and families.
• Foundation for future research into therapeutic strategies for this devastating neurological disorder.